According to Swedish Orphan Biovitrum's latest financial reports the company has C$0.14 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2024-12-31 | C$0.14 B | 24.64% |
2023-12-31 | C$0.11 B | -32.96% |
2022-12-31 | C$0.17 B | 20.65% |
2021-12-31 | C$0.14 B | 134.01% |
2020-12-31 | C$62.9 M | -38.93% |
2019-12-31 | C$0.10 B | -77.36% |
2018-12-31 | C$0.45 B | 100.19% |
2017-12-31 | C$0.22 B | 95.44% |
2016-12-31 | C$0.11 B | -22% |
2015-12-31 | C$0.14 B | 91.82% |
2014-12-31 | C$77.71 M | 5.15% |
2013-12-31 | C$73.9 M | 5.74% |
2012-12-31 | C$69.89 M | 115.7% |
2011-12-31 | C$32.4 M | 468.57% |
2010-12-31 | C$5.69 M | -87.5% |
2009-12-31 | C$45.58 M | -36.19% |
2008-12-31 | C$71.44 M | -39.17% |
2007-12-31 | C$0.11 B | -23.65% |
2006-12-31 | C$0.15 B | -0.65% |
2005-12-31 | C$0.15 B | -18.33% |
2004-12-31 | C$0.18 B | 770.53% |
2003-12-31 | C$21.77 M | 13.53% |
2002-12-31 | C$19.18 M |